Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Loes I. van Eijk"'
Autor:
Ruud P.M. Dings, Xuemei Chen, Loes I. van Eijk, Debby M.E.I. Hellebrekers, Arjan W. Griffioen, Thomas R. Hoye, Kevin H. Mayo, Ying Zhang
Publikováno v:
JNCI: Journal of the National Cancer Institute. 98:932-936
The inhibition of angiogenesis is a promising avenue for cancer treatment. Although some angiostatic compounds are in the process of development and testing, these often prove ineffective in vivo or have unwanted side effects. We have designed, synth
Autor:
Arjan W. Griffioen, Guoping Wu, Frank Mortari, Loes I. van Eijk, Yuk Y. Sham, Arne Slungaard, Arkadiusz Z. Dudek, Irina V. Nesmelova, Kevin H. Mayo
Publikováno v:
Journal of Biological Chemistry. 280:4948-4958
The apparent complexity of biology increases as more biomolecular interactions that mediate function become known. We have used NMR spectroscopy and molecular modeling to provide direct evidence that tetrameric platelet factor-4 (PF4) and dimeric int
Autor:
Arjan W. Griffioen, Judy Haseman, Dinesha Walek, Daisy W. J. van der Schaft, Irina V. Nesmelova, Thomas R. Hoye, Kevin H. Mayo, Balasz Hargittai, Ruud P.M. Dings, Loes I. van Eijk, Carolee Flader
Publikováno v:
Journal of Biological Chemistry, 278(46), 45746-45752. American Society for Biochemistry and Molecular Biology Inc.
Based on structure-activity relationships of the angiostatic beta-sheet-forming peptide anginex, we have designed a mimetic, 6DBF7, which inhibits angiogenesis and tumor growth in mice. 6DBF7 is composed of a beta-sheet-inducing dibenzofuran (DBF)-tu
Autor:
Willy Landuyt, Philippe Lambin, Bisan Ahmed, Susan R. Joosten-Achjanie, Arjan W. Griffioen, Anita van Esch, Daisy W. J. van der Schaft, Loes I. van Eijk, Jessica C.A. Bouma-ter Steege
Publikováno v:
International Journal of Cancer, 105(1), 20-25. Wiley-Liss Inc.
The current research aimed to define hypothesis-based anti-angiogenic properties of the vascular targeting agent combretastatin A-4 phosphate (combreAp). The in vitro wound assay indicated that combreAp potently inhibited migration of endothelial cel
Autor:
Annemiek W. Nap, Loes I. van Eijk, John Wagstaff, Regina G. H. Beets-Tan, Ruud P.M. Dings, Daisy W. J. van der Schaft, Arjan W. Griffioen, Jessica C.A. Bouma-ter Steege, Kevin H. Mayo, Quido G. de Lussanet
Publikováno v:
The FASEB Journal, 16, 1991-1993. FASEB
The de novo designed angiogenesis inhibitor anginex was tested in vitro and in vivo for its mechanism of action and antitumor activity. The data presented here demonstrate that anginex is a powerful antiangiogenic agent with significant antitumor act
Autor:
Loes I. van Eijk, Kevin H. Mayo, Xuemei Chen, Debby M.E.I. Hellebrekers, Jacques Maxwell, Irina V. Nesmelova, Thomas R. Hoye, Arjan W. Griffioen, Judith R. Haseman, Ruud P.M. Dings
Publikováno v:
The FASEB Journal. 20
Autor:
Arjan W. Griffioen, Ruud P.M. Dings, Judy Haseman, Nathan A. Lockwood, Loes I. van Eijk, Monica M. Arroyo, Kevin H. Mayo
Publikováno v:
The Biochemical journal. 373(Pt 1)
Anginex is a designed peptide 33mer that functions as a cytokine-like agent to inhibit angiogenesis. Although this short linear peptide has been shown by NMR and CD to form a nascent β-sheet conformation in solution, the actual bioactive structure f
Autor:
Bisan Ahmed, Loes I. van Eijk, Jessica C.A. Bouma-ter Steege, Daisy W.J. van der Schaft, Anita M. van Esch, Susan R. Joosten-Achjanie, Philippe Lambin, Willy Landuyt
Publikováno v:
International Journal of Cancer; 5/20/2003, Vol. 105 Issue 1, p20, 6p